The Q1 results confirm accelerating COVID-19 revenue erosion and deepening operating losses as the company invests heavily in oncology pipeline. The $1.0B buyback provides a floor but does not offset fundamental deterioration. The manufacturing consolidation signals management's recognition of overcapacity but carries execution risk and upfront costs. Key catalysts to watch: Phase 2 pumitamig data at ASCO (May 29-June 2), trastuzumab pamirtecan BLA filing timeline, and interim data from multiple late-stage trials expected through 2026.
Price Chart
Executive Summary
BioNTech reported Q1 2026 results with total revenue of €118.1M, down 35% YoY from €182.8M, driven by a 50% decline in COVID-19 vaccine revenue to €66.9M. Net loss widened to €531.9M (€2.10 per share) from €415.8M (€1.73 per share) in Q1 2025, as R&D spending increased 6% to €557.0M and operating loss grew to €677.5M. Post-period, the company announced a $1.0B ADS repurchase program and a major manufacturing footprint consolidation affecting up to ~2,000 positions across multiple sites.
Key Facts
- Q1 2026 total revenue €118.1M, down 35% YoY from €182.8M
- COVID-19 vaccine revenue fell 50% YoY to €66.9M
- Net loss widened to €531.9M (€2.10/share) from €415.8M (€1.73/share)
- Operating loss increased to €677.5M from €534.1M
- R&D expenses rose 6% to €557.0M; sales & marketing up 104% to €27.9M
- Cash & investments totaled €16.76B as of March 31, 2026
- Post-period: $1.0B ADS repurchase program authorized
- Post-period: Manufacturing consolidation to exit Idar-Oberstein, Marburg, Singapore, and CureVac sites affecting ~1,860 positions; JPT exit affecting ~140 positions
- Impairment of €29.9M on BNT331 program (paused)
- Pipeline prioritization costs of €18.7M in Q1
Financial Impact
Revenue decline of €64.7M (35% YoY); net loss increase of €116.1M (28% YoY); operating loss increase of €143.4M (27% YoY)
Risk Factors
- Continued COVID-19 revenue decline with no near-term replacement revenue stream
- Manufacturing consolidation execution risk and potential cash costs
- Multiple ongoing patent litigations (Moderna, GSK, Arbutus, Bayer) with uncertain outcomes
- Heavy R&D spend may not yield approved products for years
- Pipeline prioritization may lead to further program discontinuations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000031 |
| Document: form6-kq12026quarterlyrepo.htm | 0001776985-26-000031 |
| Document: 0001776985-26-000031-index-headers.html | 0001776985-26-000031 |
| Document: 0001776985-26-000031-index.html | 0001776985-26-000031 |
| Document: 0001776985-26-000031.txt | 0001776985-26-000031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access